DDInter899 DDInter505
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.
Desirudin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Desirudin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Desirudin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Selumetinib
Desirudin {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Desirudin {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Desirudin may lead to a major life threatening interaction when taken with Apixaban
Desirudin may lead to a major life threatening interaction when taken with Betrixaban